Improving neoadjuvant chemotherapy for soft tissue sarcomas’

Project: Projects from Previous Employment

Project Details


This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS). Study aim to:
1. Understand the impact of neoadjuvant chemotherapy on the risk of recurrence and overall survival for patients with high risk STS
2. Generate comprehensive multi-omic profiling of STS pre/post NCT and treated with surgery alone to identify biomarkers of response/resistance and inform development of novel treatments and clinical trials.
3. Use digital pathology to develop an electronic STS Tissue Atlas for 5 high risk subtypes.
4. Develop and characterise patient derived models (xenograft, cell lines) of high-risk STS subtypes pre/post NCT or surgical resection
Develop models using AI and mathematical modelling to predict response therapy and recurrence risk.
5. Develop clinician facing nomogram to predict recurrence risk for high risk STS.
6. Explore the role of radiomics in assessing response to NCT in high risk STS

Key findings

Study is ongoing and Dr Nixon is leading on clinical data collection for the accelerator consortium.
AcronymPANTHR study
StatusNot started


  • accelerator award
  • CRUK
  • sarcoma
  • radiomics
  • proteomics
  • chemotherapy


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.